Lynparza approved in US for early breast cancer
14 March 2022 07:05 GMT Lynparza approved in the US as adjuvant treatment for patients withgermline BRCA-mutated HER2-negative high-risk early breast cancer First and only approved medicine targeting BRCA mutations in early breast cancer New data show Lynparza demonstrated overall survival benefit in early breast cancer AstraZeneca and MSD's Lynparza (olaparib) has been approved in the US for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after